share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 1 19:31
Summary by Futu AI
無錫藥明康德於2024年3月31日完成了一項股份回購計劃，累計回購A股股份6,519,226股，占公司總股本的0.22%。該回購操作的最高價格為人民幣58.66元/股，最低價格為人民幣45.89元/股，總共使用資金達到人民幣331,114,239.93元。此次回購是繼2024年2月5日完成的人民幣10億元A股股份回購之後的又一次行動，旨在進一步維護公司價值和股東權益。根據董事會於3月8日的決議，公司將繼續利用自有資金以集中竞价交易方式回購股份，並將回購的股份全部注銷並減少注册资本。公司承諾將嚴格遵守相關法律法規，在回購期間及時履行信息披露義務。
無錫藥明康德於2024年3月31日完成了一項股份回購計劃，累計回購A股股份6,519,226股，占公司總股本的0.22%。該回購操作的最高價格為人民幣58.66元/股，最低價格為人民幣45.89元/股，總共使用資金達到人民幣331,114,239.93元。此次回購是繼2024年2月5日完成的人民幣10億元A股股份回購之後的又一次行動，旨在進一步維護公司價值和股東權益。根據董事會於3月8日的決議，公司將繼續利用自有資金以集中竞价交易方式回購股份，並將回購的股份全部注銷並減少注册资本。公司承諾將嚴格遵守相關法律法規，在回購期間及時履行信息披露義務。
Wuxi Pharmaceutical Ming Kand completed a share repurchase program on March 31, 2024, totaling 6,519,226 shares of A shares, representing 0.22% of the company's total share capital. The highest price of the repurchase operation was RMB58.66/share and the lowest price was RMB45.89/share, and the total used capital reached RMB331,114,239.93. The repurchase is a further move following the RMB 10 billion A share buyback completed on February 5, 2024 and aims to further preserve the company's value and shareholders' interests. Pursuant to the Board's resolution of March 8, the Company will continue to use its own funds to repurchase shares in a centralized competitive manner, and to divest all repurchased shares and reduce the registered capital. The Company undertakes to strictly comply with relevant laws and regulations and to fulfill its obligation to disclose information in a timely manner during the repurchase period.
Wuxi Pharmaceutical Ming Kand completed a share repurchase program on March 31, 2024, totaling 6,519,226 shares of A shares, representing 0.22% of the company's total share capital. The highest price of the repurchase operation was RMB58.66/share and the lowest price was RMB45.89/share, and the total used capital reached RMB331,114,239.93. The repurchase is a further move following the RMB 10 billion A share buyback completed on February 5, 2024 and aims to further preserve the company's value and shareholders' interests. Pursuant to the Board's resolution of March 8, the Company will continue to use its own funds to repurchase shares in a centralized competitive manner, and to divest all repurchased shares and reduce the registered capital. The Company undertakes to strictly comply with relevant laws and regulations and to fulfill its obligation to disclose information in a timely manner during the repurchase period.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.